BiotechTube

Solriamfetol + Placebo

ApprovedUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Binge Eating Disorder

Conditions

Binge Eating Disorder

Trial Timeline

Jun 15, 2021 → Dec 30, 2024

NCT ID
NCT04602936

About Solriamfetol + Placebo

Solriamfetol + Placebo is a approved stage product being developed by Jazz Pharmaceuticals for Binge Eating Disorder. The current trial status is unknown. This product is registered under clinical trial identifier NCT04602936. Target conditions include Binge Eating Disorder.

What happened to similar drugs?

1 of 7 similar drugs in Binge Eating Disorder were approved

Approved (1) Terminated (1) Active (5)
✅Duloxetine + PlaceboEli LillyApproved
🔄Zonegran + sugar pillEisaiPhase 3
🔄dasotraline 4mg + dasotraline 6mg + PlaceboSumitomo PharmaPhase 3
🔄DasotralineSumitomo PharmaPhase 3
❌Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + PlaceboNovo NordiskPhase 3
🔄Solriamfetol 75mg, 150 mg, or 300 mgAxsome TherapeuticsPhase 3
🔄Solriamfetol 150 mg + Solriamfetol 300 mg + PlaceboAxsome TherapeuticsPhase 3

Hype Score Breakdown

Clinical
20
Activity
4
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04602936ApprovedUNKNOWN

Competing Products

11 competing products in Binge Eating Disorder

See all competitors
ProductCompanyStageHype Score
Duloxetine + PlaceboEli LillyApproved
43
Zonegran + sugar pillEisaiPhase 3
40
Dasotraline + PlaceboSumitomo PharmaPhase 2/3
38
dasotraline 4mg + dasotraline 6mg + PlaceboSumitomo PharmaPhase 3
40
DasotralineSumitomo PharmaPhase 3
40
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + PlaceboNovo NordiskPhase 3
32
Sodium OxybateJazz PharmaceuticalsPhase 2/3
35
Solriamfetol 75mg, 150 mg, or 300 mgAxsome TherapeuticsPhase 3
44
Solriamfetol 150 mg + Solriamfetol 300 mg + PlaceboAxsome TherapeuticsPhase 3
44
RDC-0313 (ALKS 33) + PlaceboAlkermesPhase 2
32
ACT-539313 + PlaceboIdorsiaPhase 2
29